H.R. 2101 · 114th Congress
Research for All Act of 2015
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 114th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
CooperSponsor10 cosponsors · 9 D, 1 R
R
Lummis
ZL
D
Lofgren
RD
D
DeLauro
HJ
D
Jeffries
JS
D
Schakowsky
MW
D
Waters
JN
D
Nadler
JH
D
Himes
KR
D
Rice
NV
D
Velázquez1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill directs the Food and Drug Administration (FDA) to ensure that the clinical trials for products granted expedited approval to treat a serious or life-threatening condition are sufficient to determine the safety and effectiveness of the products for men and women using subgroup analysis.
What it does: CRS summary · Introduced in House · Apr 29, 2015
Research for All Act of 2015
This bill directs the Food and Drug Administration (FDA) to ensure that the clinical trials for products granted expedited approval to treat a serious or life-threatening condition are sufficient to determine the safety and effectiveness of the products for men and women using subgroup analysis.
This bill amends the Federal Food, Drug, and Cosmetic Act to require the FDA, at the request of the drug sponsor, to facilitate development and expedite review of a new drug that is:
- intended to avoid serious adverse events or to treat a serious or life-threatening condition,
- intended for safer or more effective treatment for either men or women than a product approved to treat the general population or the other sex, and
- supported by results of clinical trials that separately examine outcomes for men and women.
This bill amends the Public Health Service Act to require the National Institutes of Health (NIH) to ensure that, when appropriate, basic research projects include both male and female cells, tissues, or animals. In such projects, results must be disaggregated according to sex and sex differences must be examined and analyzed. NIH must update guidelines on inclusion of women and minorities in research.
The Department of Health and Human Services may support the continued operation and expansion of Special Centers of Research on Sex Differences.
The Government Accountability Office must update the reports entitled “Women's Health: NIH Has Increased Its Efforts To Include Women in Research” and “Women's Health: Women Sufficiently Represented in New Drug Testing, But FDA Oversight Needs Improvement,” and include specified examinations.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Research for All Act of 2015
Latest action (May 1, 2015): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Apr 29, 2015
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.